Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx Prices $6M Public Offering

NEW YORK — VolitionRx announced Friday it has priced an underwritten public offering of 3 million of its common shares at $2.00 each for gross proceeds of $6 million.

The Austin, Texas-based epigenetics firm plans to use the proceeds toward research, product development, clinical studies, product commercialization, working capital, and other general corporate purposes such as potential acquisitions.

Volition has granted its underwriter a 30-day option to buy up to 450,000 additional shares at the public offering prices. Volition officials expect to close the offering about Aug. 2.

Newbridge Securities is the bookrunning manager for the proposed offering.

In early morning trading Friday, shares of Volition were up about 5 percent to $2.28 per share on the Nasdaq.

In May, Volition officials said the company had $23.7 million in cash and cash equivalents as of March 31. The firm previously had a public offering targeting $20 million in gross proceeds in early 2021.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.